An algorithm for the initial assessment and management of malaria in adults has been developed jointly by the Advisory Committee on Malaria Prevention in UK Travellers (ACMP) and the British Infection Society. This has been specifically designed to help non-infection healthcare professionals, should they encounter a possible malaria case. The Algorithm can be accessed at http://www.britishinfection.org/.
The UK malaria treatment guidelines (below) were formulated by the ACMP. These guidelines are intended to define best practice for malaria treatment in the UK healthcare setting.
The authors regret that there was some confusion between mg/kg and mg/day in the penultimate paragraph of the above referenced manuscript. The corrected paragraph is reproduced below.
"The standard therapeutic dose of 15 mg primaquine base/day for 14 days is appropriate for the radical treatment of P. ovale. Certain geographical strains of P. vivax have long been recognised to possess innate resistance to primaquine and require higher doses of primaquine to prevent relapse.55 However, there has been increasing evidence of failure of standard dose primaquine from other geographical areas: clinical relapse occurs in the UK in more than 10% of patients with imported vivax treated with chloroquine followed by unsupervised primaquine 15 mg/day for 14 days.56 Higher dose primaquine 30 mg/day is more effective than 15 mg/day in South Asia, the source of most UK infections.57,58 We therefore recommend that in vivax malaria, primaquine should be given at a dose of 30 mg/day for 14 days to prevent relapse after initial treatment with chloroquine."
Last reviewed: 3 February 2011